Luckily, I was able to see Professor Ivan Goldberg in Sydney, where I have had surgery on my left eye and treatment with drops, and many thorough check-ups and tests on both eyes.
Thursday the 16th of May 2024, marks Global Accessibility Awareness Day, a key date in our calendar to get everyone talking, thinking, and learning about digital access and inclusion.
During the past decade, glaucoma care in the UK has changed dramatically, with more non-medical ophthalmic practitioners involved. As such, optometrists and other non-medical professionals have been delivering laser treatments including SLT in the Hospital Eye Service (HES).
Funding research to enhance glaucoma detection, treatment, and the lives of individuals with glaucoma is fundamental to Glaucoma Australia's mission to prevent glaucoma blindness.
Researchers have identified a potentially transformative factor for regenerating damaged optic nerves, which they believe could one day prevent irreversible blindness.
Glaucoma Australia is thrilled to welcome Senior Orthoptist Patient Educator Val Tosswill to provide comprehensive support to patients enrolled in its SiGHTWiSE Patient Support Program.
The landmark Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial – that ultimately recommended selective laser trabeculoplasty (SLT) as a first-line glaucoma intervention – has published six-year results further demonstrating the clinical effectiveness of the treatment.
To accommodate an ageing population, glaucoma management is transitioning from reactive treatment regimens to proactive ones. Three key experts detail what this mindset shift entails and how they employ it in practise.
As issues with compliance and a reduction of life-quality are commonly associated with eye drops, the industry is exploring new avenues that are revolutionising the treatment landscape.